Outputs (2)

Opportunities and challenges to delivering a trial for depressive symptoms in primary care during the COVID-19 pandemic: insights from the Alpha-Stim-D randomised controlled trial (2025)
Journal Article
Patel, S., Patel, P., Boutry, C., Guo, B., Butler, D., Higton, F., McNaughton, R., Briley, P. M., Griffiths, C., Nixon, N., Prasad, V., Sayal, K., Smart, D., Zafar, A., Kai, J., & Morriss, R. (2025). Opportunities and challenges to delivering a trial for depressive symptoms in primary care during the COVID-19 pandemic: insights from the Alpha-Stim-D randomised controlled trial. Trials, 26(1), Article 62. https://doi.org/10.1186/s13063-025-08772-3

Background
Randomised controlled trials (RCTs) are widely regarded as the most powerful research design for evidence-based practice. However, recruiting to RCTs can be challenging resulting in heightened costs and delays in research completion and i... Read More about Opportunities and challenges to delivering a trial for depressive symptoms in primary care during the COVID-19 pandemic: insights from the Alpha-Stim-D randomised controlled trial.

Acceptability, tolerability and safety of the BRIGhTMIND trial: Connectivity-guided intermittent theta-burst stimulation versus F3- repetitive transcranial magnetic stimulation for treatment-resistant depression. (2024)
Journal Article
Webster, L., Boutry, C., Thomson, L., Abdelghani, M., Barber, S., Briley, P. M., Kurkar, M., Lankappa, S., McAllister-Williams, R. H., Suazo Di Paola, A., & Morriss, R. (2024). Acceptability, tolerability and safety of the BRIGhTMIND trial: Connectivity-guided intermittent theta-burst stimulation versus F3- repetitive transcranial magnetic stimulation for treatment-resistant depression. Comprehensive Psychiatry, 136, Article 152544. https://doi.org/10.1016/j.comppsych.2024.152544

Background

The BRIGhTMIND study was a double-blind RCT comparing repetitive transcranial magnetic stimulation at a standard simulation site (the “F3” location given by the International 10–20 system, F3-rTMS) versus connectivity-guided intermitten... Read More about Acceptability, tolerability and safety of the BRIGhTMIND trial: Connectivity-guided intermittent theta-burst stimulation versus F3- repetitive transcranial magnetic stimulation for treatment-resistant depression..